November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Myeloma Paper of the Day, July 4th, suggested by Robert Orlowski
Jul 4, 2024, 10:52

Myeloma Paper of the Day, July 4th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

Myeloma Paper of the Day: Patients with t(11;14) AL (amyloidosis) who progress or have an inadequate response on Darzalex therapy have excellent responses to venetoclax with hematologic response rate 97%, and excellent organ responses (74% in cardiac, 46% in renal).

Source: Robert Orlowski/X

Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy

Authors: Danai Dima, Michael Hughes, Mark Orland, Fauzia Ullah, Utkarsh Goel, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Divaya Bhutani, Louis Williams, Suzanne Lentzsch, Christy Samaras, Jason Valent, Rajshekhar Chakraborty and Jack Khouri.

Myeloma Paper of the Day, July 4th, suggested by Robert Orlowski

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.

Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.